Drug intelligence / Profile preview

WEG-232

Development stage: Preclinical
Lead developer: Hoth Therapeutics
Modality: Small Molecules
Administration: Topical, Systemic

Overview

WEG-232 is a drug candidate being developed by Hoth Therapeutics in collaboration with George Washington University. It is being investigated as a therapy to mitigate dermatological side-effects, such as skin rashes and hair loss, that are caused by the cancer drug Erlotinib. The development is currently in the preclinical stage, with plans to manufacture GMP materials and pursue a Pre-IND consultation with the FDA, aiming towards an IND filing.

Other names: WEG232WEG-232WEG 232HT 001HT001HT-001

Targets

TACR1 (Neurokinin‑1 Receptor)

Beyond the preview

Go deeper on WEG-232.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WEG-232.

Explore the full profile